跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CNJ-016 - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
CNJ-016
Authorized
STANDARD
CNJ-016
Emergent Biosolutions Canada Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d0dd95893dd4ce09
Company
Emergent Biosolutions Canada Inc.
Type
Standard
Approval Details
Approval Id
d0dd95893dd4ce09
Drug Approval Canada Name
CNJ-016
Product Name
CNJ-016
Status
Restricted Access
Status Date
2017-09-20
Din
02295741
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D
Ahfs
80:04.00
Atc Original
J06BB07 VACCINIA IMMUNOGLOBULIN
Atc Name
j 06 bb 07
Aig Number
0152217001
Company Name
Emergent Biosolutions Canada Inc.
Company Address
155 Innovation Drive, Winnipeg, Manitoba, Canada, R3T 5Y3
Company Detail Path
/organization/emergent-biosolutions-canada-inc
Company Information
Pharmaceutical Company Name
Emergent Biosolutions Canada Inc.
Country Name
Canada
Province Name
Ontario
City Name
toronto,ontario,country_ca
Address
100 King St W
Active Ingredients
VACCINIA IMMUNOGLOBULIN (HUMAN)
50000 UNIT / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d0dd95893dd4ce09
Type
Standard
Back to Health Canada Approvals